Please assess the completion status of the following clinical trial:

Trial Title: Performance and Safety of Otinova® Ear Spray

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 5 years old~* Clinical diagnosis of otitis externa based on otoscopic exam:~  a.Defined as a clinical score of at least 1, on a scale from 0 to 2 (none, mild/moderate, severe), for at least one of the OE signs (swelling, erythema and otorrhea)~* Ability to correctly administer Otinova as spray (not requiring tamponade), as judged by the Investigator~* Subject agrees to refrain from water immersion of the ears during the investigation~* Subject agrees to refrain from using other ear treatment products during the investigation~* For pediatric patients, provision of informed consent by subject and legal -Subject, and if applicable legal representative(s), are willing to comply with the protocol and attend all investigation visits.~Exclusion Criteria:~* Duration of OE signs/symptoms longer than 6 weeks~* Suspected perforated eardrum or eardrum fitted with drainage tube~* Post-mastoid surgery~* Prior otologic surgery within 6 months of enrollment (must be successfully healed)~* Conditions which may make it difficult to evaluate the therapeutic response (e.g malignant OE, abscess, granulation, polyps, congenital disorders)~* History of malignant tumors in the external ear canal, or currently receiving chemotherapy or radiation therapy~* Known allergy or sensitivity to any component of the device~* Use of topical or systemic antibiotics, corticosteroids or other treatment that could affect the study result within 7 days prior to enrolment~* Pregnancy or lactation at time of enrolment~* Subjects with any other condition that, as judged by the investigator, may make investigation procedures inappropriate~* Participation in another clinical investigation within 30 days of screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Otinova® Ear Spray (Type: EXPERIMENTAL): Otinova® Ear Spray 1-2 sprays, twice daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).